TERN-601
Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets
Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML
Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results
Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601
Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial
Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment